Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on Next Generation Cancer therapies, has announced two strategic initiatives: securing an undisclosed strategic investment and exploring cryptocurrency treasury strategies.
The company is evaluating blockchain-based assets as a potential avenue to diversify its capital base and enhance financial flexibility while funding clinical development programs. This approach aims to reduce shareholder dilution and position Processa at the biotech-fintech intersection.
To implement its cryptocurrency treasury strategy, Processa has engaged LifeSci Capital, LLC as an advisor.
Processa Pharmaceuticals (Nasdaq: PCSA), un'azienda biofarmaceutica in fase clinica focalizzata sulle terapie oncologiche di nuova generazione, ha annunciato due iniziative strategiche: l'ottenimento di un investimento strategico non divulgato e l'esplorazione di strategie di tesoreria basate sulle criptovalute.
L'azienda sta valutando asset basati su blockchain come possibile via per diversificare la propria base di capitale e aumentare la flessibilità finanziaria, sostenendo al contempo i programmi di sviluppo clinico. Questo approccio mira a ridurre la diluizione per gli azionisti e a posizionare Processa all'incrocio tra biotecnologia e fintech.
Per attuare la sua strategia di tesoreria in criptovalute, Processa ha incaricato LifeSci Capital, LLC come consulente.
Processa Pharmaceuticals (Nasdaq: PCSA), una empresa biofarmacéutica en etapa clínica enfocada en terapias oncológicas de próxima generación, ha anunciado dos iniciativas estratégicas: asegurar una inversión estratégica no revelada y explorar estrategias de tesorería con criptomonedas.
La compañía está evaluando activos basados en blockchain como una posible vía para diversificar su base de capital y mejorar la flexibilidad financiera mientras financia programas de desarrollo clínico. Este enfoque busca reducir la dilución de los accionistas y posicionar a Processa en la intersección entre biotecnología y fintech.
Para implementar su estrategia de tesorería en criptomonedas, Processa ha contratado a LifeSci Capital, LLC como asesor.
Processa Pharmaceuticals (나스닥: PCSA)는 차세대 암 치료제에 집중하는 임상 단계의 바이오제약 회사로서 두 가지 전략적 이니셔티브를 발표했습니다: 비공개 전략적 투자 확보와 암호화폐 재무 전략 탐색입니다.
회사는 임상 개발 프로그램 자금 조달을 지원하는 동시에 자본 기반을 다각화하고 재무 유연성을 높이기 위한 방안으로 블록체인 기반 자산을 평가하고 있습니다. 이 접근법은 주주 희석을 줄이고 Processa를 바이오테크와 핀테크의 교차점에 위치시키는 것을 목표로 합니다.
암호화폐 재무 전략을 실행하기 위해 Processa는 LifeSci Capital, LLC를 자문사로 선정했습니다.
Processa Pharmaceuticals (Nasdaq : PCSA), une société biopharmaceutique en phase clinique spécialisée dans les thérapies oncologiques de nouvelle génération, a annoncé deux initiatives stratégiques : l'obtention d'un investissement stratégique non divulgué et l'exploration de stratégies de trésorerie en cryptomonnaies.
L'entreprise évalue les actifs basés sur la blockchain comme une voie potentielle pour diversifier sa base de capital et améliorer la flexibilité financière tout en finançant ses programmes de développement clinique. Cette approche vise à réduire la dilution des actionnaires et à positionner Processa à l'intersection de la biotechnologie et de la fintech.
Pour mettre en œuvre sa stratégie de trésorerie en cryptomonnaies, Processa a fait appel à LifeSci Capital, LLC en tant que conseiller.
Processa Pharmaceuticals (Nasdaq: PCSA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Krebs-Therapien der nächsten Generation, hat zwei strategische Initiativen angekündigt: die Sicherung einer nicht offengelegten strategischen Investition und die Erkundung von Kryptowährungs-Treasury-Strategien.
Das Unternehmen prüft blockchain-basierte Vermögenswerte als möglichen Weg, um seine Kapitalbasis zu diversifizieren und die finanzielle Flexibilität zu erhöhen, während klinische Entwicklungsprogramme finanziert werden. Dieser Ansatz zielt darauf ab, die Verwässerung der Aktionäre zu reduzieren und Processa an der Schnittstelle von Biotechnologie und Fintech zu positionieren.
Zur Umsetzung seiner Kryptowährungs-Treasury-Strategie hat Processa LifeSci Capital, LLC als Berater engagiert.
- Secured new strategic investment to support operations
- Exploring innovative funding strategies to reduce shareholder dilution
- Engaged LifeSci Capital as advisor for crypto treasury implementation
- Cryptocurrency investment strategy introduces new market volatility risks
- Lack of disclosure regarding strategic investment terms and amount
- Potential regulatory uncertainties surrounding crypto treasury operations
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.
We believe that strategic engagement with emerging financial technologies, including select cryptocurrencies with potential yield-generating capabilities, may offer novel avenues to diversify our capital base and enhance financial flexibility, while providing an opportunity for long-term value creation.
While we remain committed to rigorous compliance with all applicable regulatory standards, we recognize the potential for blockchain-based assets to contribute meaningfully to the funding of our clinical development programs. This approach could allow us to reduce dilution for existing shareholders, access additional sources of capital, and position the company at the forefront of biotech-fintech convergence.
We are evaluating these opportunities with a focus on long-term value creation, transparency, and responsible stewardship of investor capital.
George Ng, CEO of Processa stated, “We continue to deliver on the operational commitments, seeking meaningful therapies for patients, while exploring innovative financial strategies that can support optimal outcomes for Processa’s shareholders and stakeholders.”
Processa has also engaged LifeSci Capital, LLC in an advisory capacity in connection with implementing its cryptocurrency treasury strategy.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path. In addition to its core oncology programs, Processa is actively pursuing strategic partnerships for non-oncology assets to unlock additional value.
For more information, visit our website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
PCSA@redchip.com
FAQ
What strategic initiatives did Processa Pharmaceuticals (PCSA) announce in August 2025?
How does Processa Pharmaceuticals plan to use cryptocurrency in its treasury strategy?
Who is advising Processa Pharmaceuticals (PCSA) on its cryptocurrency treasury strategy?
What is the potential impact of PCSA's crypto treasury strategy on shareholders?
What type of company is Processa Pharmaceuticals (PCSA)?
